Moody National Bank Trust Division Sells 67 Shares of Stryker Co. (NYSE:SYK)

Moody National Bank Trust Division reduced its position in shares of Stryker Co. (NYSE:SYK – Get Rating) by 1.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,369 shares of the medical technology company’s stock after selling 67 shares during the period. Moody National Bank Trust Division’s holdings in Stryker were worth $824,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in SYK. Fairfield Bush & CO. acquired a new position in Stryker in the 1st quarter valued at approximately $131,000. Dimensional Fund Advisors LP grew its stake in shares of Stryker by 1.4% in the first quarter. Dimensional Fund Advisors LP now owns 673,924 shares of the medical technology company’s stock worth $180,182,000 after purchasing an additional 9,026 shares during the last quarter. Prudential PLC acquired a new stake in Stryker in the first quarter valued at $1,444,000. Sequoia Financial Advisors LLC raised its position in Stryker by 21.6% during the 1st quarter. Sequoia Financial Advisors LLC now owns 3,056 shares of the medical technology company’s stock worth $817,000 after purchasing an additional 543 shares during the last quarter. Finally, Zions Bancorporation N.A. lifted its holdings in Stryker by 9.2% during the 1st quarter. Zions Bancorporation N.A. now owns 3,140 shares of the medical technology company’s stock worth $839,000 after buying an additional 265 shares during the period. Institutional investors and hedge funds own 77.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on SYK. Cowen raised their price objective on Stryker from $233.00 to $283.00 in a research report on Wednesday, December 14th. BTIG Research boosted their price target on shares of Stryker from $268.00 to $281.00 and gave the stock a “buy” rating in a research report on Wednesday, February 1st. KeyCorp started coverage on shares of Stryker in a research report on Wednesday, January 25th. They set a “sector weight” rating for the company. StockNews.com started coverage on shares of Stryker in a report on Thursday. They issued a “buy” rating on the stock. Finally, Evercore ISI increased their price target on Stryker to $265.00 in a report on Tuesday, January 3rd. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $270.79.

Stryker Price Performance

Shares of SYK opened at $274.44 on Friday. The business’s fifty day moving average is $263.78 and its 200 day moving average is $238.53. Stryker Co. has a 12-month low of $188.84 and a 12-month high of $284.00. The company has a quick ratio of 1.00, a current ratio of 1.63 and a debt-to-equity ratio of 0.71. The stock has a market cap of $103.97 billion, a P/E ratio of 44.48, a P/E/G ratio of 2.82 and a beta of 0.93.

Stryker (NYSE:SYK – Get Rating) last released its quarterly earnings data on Tuesday, January 31st. The medical technology company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.16. The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $4.97 billion. Stryker had a net margin of 12.78% and a return on equity of 22.39%. The business’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same period last year, the firm earned $2.71 earnings per share. Sell-side analysts anticipate that Stryker Co. will post 10.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 28th. Shareholders of record on Friday, March 31st will be issued a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 1.09%. The ex-dividend date is Thursday, March 30th. Stryker’s dividend payout ratio is currently 48.62%.

Insider Transactions at Stryker

In related news, insider James Andrew Pierce sold 400 shares of the company’s stock in a transaction on Thursday, February 2nd. The stock was sold at an average price of $277.88, for a total transaction of $111,152.00. Following the completion of the sale, the insider now owns 46,676 shares in the company, valued at $12,970,326.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, insider James Andrew Pierce sold 400 shares of the business’s stock in a transaction dated Thursday, February 2nd. The shares were sold at an average price of $277.88, for a total transaction of $111,152.00. Following the transaction, the insider now directly owns 46,676 shares in the company, valued at $12,970,326.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP M Kathryn Fink sold 6,571 shares of the stock in a transaction dated Wednesday, January 11th. The shares were sold at an average price of $257.69, for a total transaction of $1,693,280.99. Following the completion of the sale, the vice president now owns 9,264 shares of the company’s stock, valued at approximately $2,387,240.16. The disclosure for this sale can be found here. Insiders sold a total of 357,410 shares of company stock valued at $97,831,003 over the last ninety days. 6.70% of the stock is currently owned by insiders.

About Stryker

(Get Rating)

Stryker Corp. is a medical technology company, which engages in the provision of innovative products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery.